Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS AUGUST ISSUE PUBLISHED
  • AUGUST 2020 Issue has been successfully launched on 1 August 2020.

Abstract

PATIENTS AS A SOURCE FOR COSTS DATA FOR RHEUMATOID ARTHRITIS THERAPY– PILOT STUDY

*Lubomir Marinov, Valentina Petkova, Irina Nikolova, Alexandra Savova,Guenka Petrova

1Medical University – Sofia, Faculty of Pharmacy, Department of Pharmacology, toxicologyand pharmacotherapy, Dunav str., Sofia 1000, BULGARIA.

2Medical University – Sofia, Faculty of Pharmacy, Department of Organisation and economyof Pharmacy, Dunav str., Sofia 1000, BULGARIA.

ABSTRACT

The goal of this pilot study is to perform a cost analysis by using patients with rheumatoid arthritis as a source of information. The point of view is that of the patients and society and the time horizon is one year. It is a micro costing study calculating the direct health care cost of pharmacotherapy. The pharmacotherapy includes 6 main therapeutic groups of medicines as corticosteroids (per os or intraarticular injections), disease modifying antirheumatics (DMAR), biological, non-steroidal anti-inflammatory drugs (NSAID), medicines improving bone density, and proton pump inhibitors (PPI).Monthly cost of pharmacotherapy per patient on average is 815.05 (SD 1104.25) BGN, and biological therapy is the most expensive one 2961.03 (SD 1435.46). 25% of the patients are on it. 58 per cent of the patients reported regular physicians’ visits at least ones quarterly with average yearly cost of 111.60 BGN (9.30 BGN per month). 56 people were out of work and for 13 of them it was for more than 20 days (6.18 days per patient per year on average). This consumes 147.17 BGN per patient per year (12.26 BGN per month). 85 people were hospitalized during the year and this consumes 589.65 BGN per patient per year (49.13 BGN per month). The structure of the monthly cost per patient with RA shows that pharmacotherapy is with the highest value with relative share (92%) out of the observed health and non health care resources used. The next cost by value is the hospitalization cost (6%). The cost of RA is high and medicines are the main cost drivers. Micro-costing based on patients as source of information is not completely reliable and provides subjective information about the cost of the therapy.

Keywords: pharmacotherapy, rheumatoid arthritis, cost of illness, patients reported cost.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More